Compare Davita Inc (DVA) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Kyndryl Holdings Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Kyndryl Holdings Inc trades at $11.76 (market cap $2.49B). The key difference: Davita Inc is far larger — about 4.5× Kyndryl Holdings Inc's market cap, and Davita Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Kyndryl Holdings Inc for 36 Days on average.
| DVA | KD | |
|---|---|---|
Market Cap | $11.28B | $2.49B |
Volume | 650,294 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $240.96 | $29.76 |
52-Week Low | $103.87 | $10.59 |
Typical Hold Time | 113 Days | 36 Days |
Enterprise Value | $24.00B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Kyndryl (KD) trades at $11.88, up 3.48% today, with a bearish technical signal and mixed earnings. Revenue declined to $15.06B in 2025, but net income turned positive at $252M, marking a recovery from prior losses. The company is actively investing in AI, as highlighted by recent news of an AI innovation lab and acquisitions. Analyst consensus is mostly hold, with a $14.67 price target suggesting moderate upside.
The outlook hinges on AI-driven growth offsetting revenue pressures, but risks include high debt, competitive IT services market, and inconsistent earnings. Institutional sentiment is cautious, with weak technical trends near key support. Upside depends on execution of modernization contracts and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
